Cover Image
市場調查報告書

非酒精性脂肪性肝炎:全球臨床實驗趨勢

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 240574
出版日期 內容資訊 英文 245 Pages
訂單完成後即時交付
價格
Back to Top
非酒精性脂肪性肝炎:全球臨床實驗趨勢 Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016
出版日期: 2016年11月30日 內容資訊: 英文 245 Pages
簡介

本報告提供非酒精性脂肪性肝炎相關臨床研究最新趨勢相關分析,提供您疾病·治療方法概要,及G7、E7各國的臨床實驗狀況,各地區、各階段的進行狀況,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 前五名國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:非酒精性脂肪性肝炎臨床實驗數量佔消化管疾病臨床實驗數量比率

各期臨床實驗數量: G7各國

G7各國的臨床實驗數量:各期

E7各國的臨床實驗數量:非酒精性脂肪性肝炎臨床實驗數量佔消化管疾病臨床實驗數量比率

各期臨床實驗數量: E7各國

E7各國的臨床實驗數量:各期

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

一定期間所採用的受驗人數

贊助商類別臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 非酒精性脂肪性肝炎 治療藥

有潛力的藥劑

  • 最新臨床實驗新聞:非酒精性脂肪性肝炎

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3939CTIDB

GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016" provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Non-Alcoholic Steatohepatitis
      • Nov 16, 2016: Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
      • Nov 14, 2016: Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis Presented at The Liver Meeting 2016
      • Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting
      • Nov 11, 2016: Allergan Shows Strong Presence at the AASLD Liver Meeting with Data in Poster Sessions and an Oral Plenary Presentation
      • Nov 11, 2016: Enanta Announces New Data on FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting 2016
      • Nov 11, 2016: Enanta Announces New Data on EP-024297 at The Liver Meeting 2016
      • Nov 08, 2016: Promethera Biosciences to Present Preclinical Data on NASH-Fibrosis Program at 2016 AASLD Meeting
      • Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
      • Nov 01, 2016: NeuroVive Reports Positive Pre-Clinical Results in NASH
      • Nov 01, 2016: Intercept to present preclinical data on INT-767 at the 2016 AASLD Annual Meeting
      • Oct 31, 2016: DURECT Announces Update on DUR-928 Development Program
      • Oct 31, 2016: Zydus to Present New Scientific Data of Investigational Saroglitazar at the 2016 AASLD Liver Meeting in Boston, USA
      • Oct 27, 2016: Bird Rock Bio Submits Clinical Trial Authorization for the First in Human Clinical Trial for Namacizumab
      • Oct 20, 2016: Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis, Pulmonary Arterial Hypertension and Diabetic Kidney Disease
      • Oct 20, 2016: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis
      • Oct 20, 2016: Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting
      • Oct 18, 2016: ChemoCentryx CCR2 Inhibitor CCX872 Shown to Reduce Liver Fibrosis in NASH Models
      • Oct 13, 2016: Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH
      • Oct 10, 2016: NASH Phase II Trial Reaches 90 (75%) Patient Recruitment Milestone
      • Oct 07, 2016: Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis
      • Oct 06, 2016: CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclincal Model of NASH at the AASLD 2016 Liver Meeting
      • Oct 04, 2016: Viking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
      • Oct 03, 2016: Enanta Pharmaceuticals Announces New Data on EDP-305 at the Liver Meeting 2016
      • Oct 03, 2016: Enanta Pharmaceuticals To present New Data on EP-024297 at the Liver Meeting 2016
      • Oct 03, 2016: Tobira Therapeutics Announces Presentations Related to Cenicriviroc's Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting
      • Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting
      • Sep 29, 2016: Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study
      • Sep 28, 2016: Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)
      • Sep 27, 2016: Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis
      • Sep 12, 2016: Tobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin
      • Aug 31, 2016: FORMA Therapeutics Achieves Clinical Candidate Licensing Milestone for NASH Compound in Strategic Alliance with Celgene
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
  • Source

List of Tables

  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top